ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy.

abstract：:Antibodies can be used to target cancer therapies to malignant tissue; the approach is attractive because conventional treatments such as chemo- and radiotherapy are dose limited due to toxicity in normal tissues. Effective targeting relies on appropriate pharmacokinetics of antibody-based therapeutics, ideally showin...

journal_title：Cancer chemotherapy and pharmacology

authors： Chester KA,Mayer A,Bhatia J,Robson L,Spencer DI,Cooke SP,Flynn AA,Sharma SK,Boxer G,Pedley RB,Begent RH

更新日期：2000-01-01 00:00:00

abstract：:Modulators of protein kinase C (PKC) were used to investigate the role of this enzyme during Adriamycin-induced erythroid differentiation of K562 cells. Adriamycin (0.1 microM) induced erythroid differentiation in 60% +/- 10% of K562 cells. Phorbol myristate-12-acetate, an activator of protein kinase C, was strongly a...

journal_title：Cancer chemotherapy and pharmacology

authors： Hoffman R,Newlands ES

更新日期：1991-01-01 00:00:00

abstract：PURPOSE:Irinotecan-induced gut toxicity is mediated in part by Toll-Like receptor 4 (TLR4) signalling. The primary purpose of this preclinical study was to determine whether blocking TLR4 signalling by administering (-)-naloxone, a TLR4 antagonist, would improve irinotecan-induced gut toxicity. Our secondary aim was to...

journal_title：Cancer chemotherapy and pharmacology

authors： Coller JK,Bowen JM,Ball IA,Wardill HR,van Sebille YZ,Stansborough RL,Lightwala Z,Wignall A,Shirren J,Secombe K,Gibson RJ

更新日期：2017-02-01 00:00:00

abstract：:A variety of purine analogs inhibit the growth and induce the differentiation of human promyelocytic leukemia (HL-60) cells that lack the purine salvage enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRT). Mechanisms by which purine analogs induce differentiation offer unique potential for cancer chemotherap...

journal_title：Cancer chemotherapy and pharmacology

authors： Gibboney DS,French BT,Patrick DE,Trewyn RW

更新日期：1989-01-01 00:00:00

abstract：PURPOSE:To investigate the activity of combination chemotherapy with ifosfamide, 5-fluorouracil, etoposide and cisplatin in patients with metastatic urothelial cancer. METHODS:A group of 29 patients were treated with 2000 mg/m2 ifosfamide, 750 mg/m2 5-fluorouracil, 100 mg/m2 etoposide and 20 mg/m2 cisplatin. All four ...

journal_title：Cancer chemotherapy and pharmacology

authors： Fukui I,Yonese J,Tsukamoto T,Yoshida T,Kim T,Tohma T,Ishiwata D

更新日期：2001-07-01 00:00:00

abstract：PURPOSE:The addition of cetuximab to triplet chemotherapy can increase treatment efficacy for patients with metastatic colorectal cancer (mCRC). We explored the dose-limiting toxicity and feasibility of a triweekly capecitabine, oxaliplatin, irinotecan, plus cetuximab (XELOXIRI plus cetuximab) regimen in patients with ...

journal_title：Cancer chemotherapy and pharmacology

authors： Sato Y,Hirakawa M,Ohnuma H,Takahashi M,Okamoto T,Okamoto K,Miyamoto H,Muguruma N,Furuhata T,Takemasa I,Kato J,Takayama T

更新日期：2017-12-01 00:00:00

abstract：:Flavone acetic acid (FAA, NSC 347512) is a synthetic flavonoid compound with a unique form of preclinical antitumor activity, but its mechanism of action is still not known. In an attempt to exploit the remarkable preclinical activity of this compound in such a way as to allow its use as a clinically useful agent, we ...

journal_title：Cancer chemotherapy and pharmacology

authors： de Forni M,Chabot GG,Armand JP,Gouyette A,Klink-Alak M,Recondo G

更新日期：1995-01-01 00:00:00

abstract：PURPOSE:Acid ceramidase (AC) occupies an important place in the control of cancer cell proliferation. We tested the influence of AC inhibition on the effects of PSC 833, a P-glycoprotein antagonist with potent ceramide-generating capacity, to determine whether AC could be a therapeutic target in pancreatic cancer. MET...

journal_title：Cancer chemotherapy and pharmacology

authors： Morad SA,Messner MC,Levin JC,Abdelmageed N,Park H,Merrill AH Jr,Cabot MC

更新日期：2013-03-01 00:00:00

abstract：PURPOSE:The observation that the orphan drug dichloroacetate (DCA) selectively promotes mitochondria-regulated apoptosis and inhibits tumour growth in preclinical models by shifting the glucose metabolism in cancer cells from anaerobic to aerobic glycolysis attracted not only scientists', clinicians' but also patients'...

journal_title：Cancer chemotherapy and pharmacology

authors： Heshe D,Hoogestraat S,Brauckmann C,Karst U,Boos J,Lanvers-Kaminsky C

更新日期：2011-03-01 00:00:00

abstract：BACKGROUND:The objective of this study was to evaluate the efficacy and safety of concurrent immune checkpoint inhibitor therapy and radiotherapy (immunoradiotherapy) in patients with metastatic melanoma after progression on nivolumab. PATIENTS AND METHODS:A retrospective review was performed on 16 consecutive patient...

journal_title：Cancer chemotherapy and pharmacology

authors： Nomura M,Otsuka A,Yoshimura M,Nonomura Y,Kaku Y,Matsumoto S,Muto M

更新日期：2018-05-01 00:00:00

abstract：:A total of 23 patients were treated at five dose escalations with high-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. The maximum tolerated doses of cyclophosphamide, cisplatin, and melphalan were 5,625, 180, and 80 mg/m2, respectively. The dose-limiting toxicity was c...

journal_title：Cancer chemotherapy and pharmacology

authors： Peters WP,Stuart A,Klotman M,Gilbert C,Jones RB,Shpall EJ,Gockerman J,Bast RC Jr,Moore JO

更新日期：1989-01-01 00:00:00

abstract：PURPOSE:To characterize and compare pharmacokinetic parameters in children and adults treated with temozolomide (TMZ) administered for 5 days in three doses daily, and to evaluate the possible relationship between AUC values and hematologic toxicity. METHODS:TMZ pharmacokinetic parameters were characterized in pediatr...

journal_title：Cancer chemotherapy and pharmacology

authors： Riccardi A,Mazzarella G,Cefalo G,Garrè ML,Massimino M,Barone C,Sandri A,Ridola V,Ruggiero A,Mastrangelo S,Lazzareschi I,Caldarelli M,Maira G,Madon E,Riccardi R

更新日期：2003-12-01 00:00:00

abstract：BACKGROUND:3-Aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) is a novel small-molecule ribonucleotide reductase inhibitor. This study was designed to estimate the maximum tolerated dose (MTD) and oral bioavailability of 3-AP in patients with advanced-stage solid tumors. METHODS:Twenty patients received one dos...

journal_title：Cancer chemotherapy and pharmacology

authors： Chao J,Synold TW,Morgan RJ Jr,Kunos C,Longmate J,Lenz HJ,Lim D,Shibata S,Chung V,Stoller RG,Belani CP,Gandara DR,McNamara M,Gitlitz BJ,Lau DH,Ramalingam SS,Davies A,Espinoza-Delgado I,Newman EM,Yen Y

更新日期：2012-03-01 00:00:00

abstract：:Clinical evidence suggests some lack of cross resistance between vincristine (VCR) and vindesine (VDS). To investigate this phenomenon experimentally, drug-resistant L5178Y lymphoblast cell lines have been derived in vitro. These lines, under conditions of continuous drug exposure, exhibit a 50-fold order of resistanc...

journal_title：Cancer chemotherapy and pharmacology

authors： Hill BT,Whelan RD

更新日期：1982-01-01 00:00:00

abstract：PURPOSE:The dolastatins are a class of naturally occurring cytotoxic peptides which function by inhibiting microtubule assembly and tubulin polymerization. Cemadotin is a synthetic analogue of dolastatin 15 with potent antiproliferative and preclinical antitumor activity. This report describes a phase I study to evalua...

journal_title：Cancer chemotherapy and pharmacology

authors： Supko JG,Lynch TJ,Clark JW,Fram R,Allen LF,Velagapudi R,Kufe DW,Eder JP Jr

更新日期：2000-01-01 00:00:00

abstract：:When tumor cell density increases, the cytotoxic activity of certain anticancer agents, such as vincristine (VCR) and doxorubicin (DXR), progressively decreases. This phenomenon is termed the inoculum effect. Since VCR and DXR are less active in an acidic environment, we questioned whether the inoculum effects could h...

journal_title：Cancer chemotherapy and pharmacology

authors： Kobayashi H,Takemura Y,Ohnuma T

更新日期：1992-01-01 00:00:00

abstract：PURPOSE:We have previously reported that intra-arterial chemotherapy prolongs the survival of patients with advanced HCC (aHCC); however, whether the response to intra-arterial chemotherapy depends on the etiology of underlying liver cirrhosis (LC) is still unknown. AIM:The aim of this study was to assess any influenc...

journal_title：Cancer chemotherapy and pharmacology

authors： Kanayama M,Nagai H,Sumino Y

更新日期：2009-06-01 00:00:00

abstract：PURPOSE:The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) is approved for cancer treatment. We investigated whether gefitinib treatment can enhance human EGF (hEGF) uptake in vitro, thereby increasing the potential of hEGF as a vehicle for EGFR-targeted therapy. METHODS:W...

journal_title：Cancer chemotherapy and pharmacology

authors： He P,Li G

更新日期：2013-08-01 00:00:00

abstract：PURPOSE:The present study was designed to investigate the ability of N-[4-(5-bromo-2-pyrimidyloxy)-3-methylphenyl]-(dimemethylamino)-benzoylphenylurea (dimemethylamino benzoylphenylurea; BPU) to sensitize cells to radiation and to examine the relationship between phenotype versus survival, DNA damage, apoptosis, or cel...

journal_title：Cancer chemotherapy and pharmacology

authors： Balcer-Kubiczek EK,Attarpour M,Edelman MJ

更新日期：2007-05-01 00:00:00

abstract：:Chemotherapy-induced intestinal damage is a very important dose-limiting side effect for which there is no definitive prophylaxis or treatment. This is in part due to the lack of understanding of its pathophysiology and impact on intestinal differentiation. The objective of this study was to investigate the gene expre...

journal_title：Cancer chemotherapy and pharmacology

authors： de Koning BA,Lindenbergh-Kortleve DJ,Pieters R,Rings EH,Büller HA,Renes IB,Einerhand AW

更新日期：2006-06-01 00:00:00

abstract：:Marimastat (BB-2516) is the first matrix metalloproteinase inhibitor to have entered clinical trials in the field of oncology. It has excellent bioavailability and has completed phase I and II trials. Phase I studies involved healthy volunteers who received short courses of marimastat; these were well tolerated. Sympt...

journal_title：Cancer chemotherapy and pharmacology

authors： Steward WP

更新日期：1999-01-01 00:00:00

abstract：PURPOSE:Sarcomas are a rare and heterogeneous variant of cancer. The standard of care treatment involves surgical resection with radiation in high-risk patients. Despite appropriate treatment approximately 50 % of patients will suffer and die from recurrent disease. The purpose of this article is to review the current ...

journal_title：Cancer chemotherapy and pharmacology

authors： Nathenson MJ,Sausville E

更新日期：2016-11-01 00:00:00

abstract：:Pancreatic cancer is the fourth leading cause of cancer-related deaths in the USA, with a 5-year survival rate of 6 %. Anti-hyperglycemic treatments for type 2 diabetes mellitus that induce hyperinsulinemia (i.e., sulfonylureas) are thought to increase cancer risk, whereas treatments that lower insulin resistance and ...

journal_title：Cancer chemotherapy and pharmacology

authors： De Souza A,Khawaja KI,Masud F,Saif MW

更新日期：2016-02-01 00:00:00

abstract：PURPOSE:The purpose of this study was to assess the therapeutic and toxicological effects of cesium chloride (CsCl) administration in mice bearing prostate cancer tumors. METHODS:Three CsCl dose titration studies were completed in tumor-bearing and non-tumor-bearing athymic nude mice. All mice were administered either...

journal_title：Cancer chemotherapy and pharmacology

authors： Low JC,Wasan KM,Fazli L,Eberding A,Adomat H,Guns ES

更新日期：2007-11-01 00:00:00

abstract：:The oral bioavailability of methotrexate is variable and may be dose-dependent. The absorption of 'interval' oral methotrexate, which is given between cycles of chemotherapy, is unknown. The bioavailability of oral methotrexate has been studied in eight patients, acting as their own controls, to assess the effect of s...

journal_title：Cancer chemotherapy and pharmacology

authors： Harvey VJ,Slevin ML,Woollard RC,Johnston A,Barnett MJ,Wrigley PF,Turner P

更新日期：1984-01-01 00:00:00

abstract：PURPOSE:As reported, epidermal growth factor receptor (EGFR) is over expressed in a variety of cancers including esophageal squamous cell carcinoma. Therefore, it becomes one of the potential targets for treating esophageal cancer. Pingyangmycin (PYM), a single A5 component of bleomycin, is currently used for the treat...

journal_title：Cancer chemotherapy and pharmacology

authors： Gong JH,Liu XJ,Li Y,Zhen YS

更新日期：2012-05-01 00:00:00

abstract：:Cyclophosphamide (Cy) is widely used as an effective cytotoxic drug, but its use is limited because of its toxicity. In this report, we describe for the first time the ability of purified protein A (P) of Staphylococcus aureus to reduce Cy-induced toxicity in rats. Protein A-treated animals recover quickly from the to...

journal_title：Cancer chemotherapy and pharmacology

authors： Ray PK,Dohadwala M,Bandyopadhyay SK,Canchanapan P,McLaughlin D

更新日期：1985-01-01 00:00:00

abstract：PURPOSE:The survival benefit of chemotherapy (CTx) compared with best supportive care (BSC) is unclear in patients with recurrent or metastatic esophageal squamous cell carcinoma (R/M-ESCC) previously treated with fluorouracil (FU), platinum (PT), and taxane (TAX). PATIENTS AND METHODS:The data of 283 consecutive pati...

journal_title：Cancer chemotherapy and pharmacology

authors： Nomura M,Iwasa S,Tsushima T,Kato K,Yasui H,Boku N,Muto M,Muro K

更新日期：2016-12-01 00:00:00

abstract：PURPOSE:Sonidegib (Odomzo) selectively inhibits smoothened and suppresses the growth of hedgehog pathway-dependent tumors. A population pharmacokinetic (PK) analysis of sonidegib in healthy subjects and patients with advanced solid tumors was conducted to characterize PK, determine variability, and estimate covariate e...

journal_title：Cancer chemotherapy and pharmacology

authors： Goel V,Hurh E,Stein A,Nedelman J,Zhou J,Chiparus O,Huang PH,Gogov S,Sellami D

更新日期：2016-04-01 00:00:00

abstract：BACKGROUND:Epidemiologic and preclinical data suggest isoflavones have anticancer activity in colorectal malignancy prevention and treatment. This is the first clinical trial assessing safety and tolerability of Genistein in combination with chemotherapy in metastatic colorectal cancer. METHODS:Patients who had histol...

journal_title：Cancer chemotherapy and pharmacology

authors： Pintova S,Dharmupari S,Moshier E,Zubizarreta N,Ang C,Holcombe RF

更新日期：2019-09-01 00:00:00